{
  "0LW.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Neovacs S.A.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NEOVACS NOM.  EO-,05",
    "state": null,
    "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.",
    "website": "http://www.neovacs.fr",
    "zipcode": "75014"
  },
  "16O.F": {
    "city": "Dijon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Oncodesign Société Anonyme",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCODESIGN SA  EO -,08",
    "state": null,
    "summary": "Oncodesign SociÃ©tÃ© Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.",
    "website": "http://www.oncodesign.com",
    "zipcode": "21076"
  },
  "1F6.F": {
    "city": "Libourne",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Fermentalg Société Anonyme",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FERMENTALG  EO -,04",
    "state": null,
    "summary": "Fermentalg SociÃ©tÃ© Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.",
    "website": "http://www.fermentalg.com/fr",
    "zipcode": "33500"
  },
  "2E4.F": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ERYTECH Pharma S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ERYTECH PHARMA SA  EO-,10",
    "state": null,
    "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",
    "website": "http://www.erytech.com",
    "zipcode": "69008"
  },
  "2E4A.F": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ERYTECH Pharma S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ERYTECH PHARMA SP.ADR-,10",
    "state": null,
    "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",
    "website": "http://www.erytech.com",
    "zipcode": "69008"
  },
  "2X1.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ABIVAX Société Anonyme",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ABIVAX SA  EO -,01",
    "state": null,
    "summary": "ABIVAX SociÃ©tÃ© Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX SociÃ©tÃ© Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
    "website": "http://www.abivax.com",
    "zipcode": "75008"
  },
  "35L.F": {
    "city": "Romainville",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pherecydes Pharma Société anonyme",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHERECYDES PHARMA  EO 1",
    "state": null,
    "summary": "Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.",
    "website": "http://www.pherecydes-pharma.com",
    "zipcode": "93230"
  },
  "3HB.SG": {
    "city": null,
    "country": "France",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Hybrigenics Société Anonyme",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Hybrigenics S.A. Actions Nom. E",
    "state": null,
    "summary": "Hybrigenics SociÃ©tÃ© Anonyme comprises biopharmaceutical company. Hybrigenics SociÃ©tÃ© Anonyme is located in France.",
    "website": "http://www.hybrigenics.com",
    "zipcode": null
  },
  "3MM.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Advicenne S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADVICENNE (PROM.) EO-,20",
    "state": null,
    "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.",
    "website": "http://www.advicenne.com",
    "zipcode": "75002"
  },
  "3VG.F": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Theranexus Société Anonyme",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "THERANEXUS EO -,25",
    "state": null,
    "summary": "Theranexus sociÃ©tÃ© anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.",
    "website": "http://www.theranexus.com",
    "zipcode": "69008"
  },
  "4W4.F": {
    "city": "Neuilly-sur-Seine",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Lysogene S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LYSOGENE S.A.(PROM.)-,30",
    "state": null,
    "summary": "Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.",
    "website": "http://www.lysogene.com",
    "zipcode": "92200"
  },
  "5D8.F": {
    "city": "Grabels",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Deinove SA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DEINOVE  EO-,40",
    "state": null,
    "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME OlÃ©oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMÃ©rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, OlÃ©os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.",
    "website": "http://www.deinove.com",
    "zipcode": "34790"
  },
  "5NR.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Nanobiotix S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOBIOTIX INH.  EO-,03",
    "state": null,
    "summary": "Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.",
    "website": "http://www.nanobiotix.com",
    "zipcode": "75012"
  },
  "5NRA.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Nanobiotix S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOBIOTIX S.A. SP.ADR",
    "state": null,
    "summary": "Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.",
    "website": "http://www.nanobiotix.com",
    "zipcode": "75012"
  },
  "609.F": {
    "city": "Labege",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ABIONYX Pharma SA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABIONYX PHARMA SA  EO-,05",
    "state": null,
    "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
    "website": "http://abionyx.com",
    "zipcode": "31130"
  },
  "609.SG": {
    "city": "Labege",
    "country": "France",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "ABIONYX Pharma SA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABIONYX PHARMA",
    "state": null,
    "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
    "website": "http://abionyx.com",
    "zipcode": "31130"
  },
  "6IV.F": {
    "city": "Daix",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Inventiva S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INVENTIVA S.A.(PROM.)-,01",
    "state": null,
    "summary": "Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
    "website": "http://www.inventivapharma.com",
    "zipcode": "21121"
  },
  "6IVA.F": {
    "city": "Daix",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Inventiva S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INVENTIVA  ADS/1  O.N.",
    "state": null,
    "summary": "Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
    "website": "http://www.inventivapharma.com",
    "zipcode": "21121"
  },
  "6OP.F": {
    "city": "Nantes",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "OSE Immunotherapeutics SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OSE IMMUNOTHERAPE.EO -,20",
    "state": null,
    "summary": "OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as SjÃ¶gren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.",
    "website": "http://www.ose-immuno.com",
    "zipcode": "44200"
  },
  "6XB.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biophytis SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOPHYTIS NAM.",
    "state": null,
    "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.",
    "website": "http://www.biophytis.com",
    "zipcode": "75005"
  },
  "6XBA.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biophytis SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOPHYTIS  ADR/1  O.N.",
    "state": null,
    "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.",
    "website": "http://www.biophytis.com",
    "zipcode": "75005"
  },
  "76D.F": {
    "city": "Montpellier",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Medesis Pharma S.A.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDSIS PHARMA SA EO 2,-",
    "state": null,
    "summary": "Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 Â NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.",
    "website": "http://www.medesispharma.com",
    "zipcode": "34670"
  },
  "7PO.F": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Poxel S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "POXEL S.A.  EO -,02",
    "state": null,
    "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.",
    "website": "http://www.poxelpharma.com",
    "zipcode": "69007"
  },
  "8JD.F": {
    "city": "PÃ©rigny",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Valbiotis SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VALBIOTIS S.A.  EO -,10",
    "state": null,
    "summary": "Valbiotis SA engages in the research and development of health nutrition products to prevent metabolic diseases in response to unmet medical needs. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070 for hypercholesterolemia; TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease; and TOTUM-854 for arterial hypertension. It has a strategic partnership with NestlÃ© Health Science. The company was founded in 2014 and is headquartered in PÃ©rigny, France.",
    "website": "http://www.valbiotis.com",
    "zipcode": "17180"
  },
  "A89.F": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Adocia SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADOCIA SAS  EO -,10",
    "state": null,
    "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
    "website": "http://www.adocia.com",
    "zipcode": "69003"
  },
  "AAVXF": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "ABIVAX Société Anonyme",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ABIVAX",
    "state": null,
    "summary": "ABIVAX SociÃ©tÃ© Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX SociÃ©tÃ© Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
    "website": "http://www.abivax.com",
    "zipcode": "75008"
  },
  "ABNX.PA": {
    "city": "Labege",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "ABIONYX Pharma SA",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABIONYX PHARMA",
    "state": null,
    "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
    "website": "http://abionyx.com",
    "zipcode": "31130"
  },
  "ABVX.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "ABIVAX Société Anonyme",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ABIVAX",
    "state": null,
    "summary": "ABIVAX SociÃ©tÃ© Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX SociÃ©tÃ© Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
    "website": "http://www.abivax.com",
    "zipcode": "75008"
  },
  "ADOC.PA": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Adocia SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADOCIA",
    "state": null,
    "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
    "website": "http://www.adocia.com",
    "zipcode": "69003"
  },
  "ADOCY": {
    "city": "Lyon",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Adocia SA",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADOCIA",
    "state": null,
    "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
    "website": "http://www.adocia.com",
    "zipcode": "69003"
  },
  "ADVIC.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Advicenne S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADVICENNE",
    "state": null,
    "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.",
    "website": "http://www.advicenne.com",
    "zipcode": "75002"
  },
  "ALBPS.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Biophytis SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOPHYTIS",
    "state": null,
    "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.",
    "website": "http://www.biophytis.com",
    "zipcode": "75005"
  },
  "ALCLS.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Cellectis S.A.",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELLECTIS",
    "state": null,
    "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.",
    "website": "http://www.cellectis.com",
    "zipcode": "75013"
  },
  "ALDEI.PA": {
    "city": "Grabels",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Deinove SA",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DEINOVE",
    "state": null,
    "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME OlÃ©oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioMÃ©rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, OlÃ©os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.",
    "website": "http://www.deinove.com",
    "zipcode": "34790"
  },
  "ALGEN.PA": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "genOway Société anonyme",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GENOWAY",
    "state": null,
    "summary": "genOway SociÃ©tÃ© anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.",
    "website": "http://www.genoway.com",
    "zipcode": "69007"
  },
  "ALHYG.PA": {
    "city": null,
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Hybrigenics Société Anonyme",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HYBRIGENICS",
    "state": null,
    "summary": "Hybrigenics SociÃ©tÃ© Anonyme comprises biopharmaceutical company. Hybrigenics SociÃ©tÃ© Anonyme is located in France.",
    "website": "http://www.hybrigenics.com",
    "zipcode": null
  },
  "ALINT.PA": {
    "city": "Ãvry",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "IntegraGen SA",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INTEGRAGEN",
    "state": null,
    "summary": "IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. Its service solutions include DNA sequencing, transcriptomics, epigenomics, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an intuitive interface that enables users to visualize molecular tumor profile for cancer patients following the rapid analysis of their sequencing data; and offers users access to various annotation databases, links for potential clinical trials, and treatment options based on identified variants, as well as to create and export a customizable report. In addition, the company offers SIRIUS, a cloud-based software tool that enables researchers to analyse whole genome, whole exome, and gene panel sequencing data when exploring rare diseases; Galileo, a cloud-based app for dynamic exploration of RNA-Seq expression data; and GeCo, a genomic consulting service. IntegraGen SA was founded in 2000 and is headquartered in Ãvry, France.",
    "website": "http://www.integragen.com",
    "zipcode": "91000"
  },
  "ALMDP.PA": {
    "city": "Montpellier",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Medesis Pharma S.A.",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDESIS PHARMA",
    "state": null,
    "summary": "Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 Â NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.",
    "website": "http://www.medesispharma.com",
    "zipcode": "34670"
  },
  "ALNEV.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Neovacs S.A.",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NEOVACS",
    "state": null,
    "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.",
    "website": "http://www.neovacs.fr",
    "zipcode": "75014"
  },
  "ALONC.PA": {
    "city": "Dijon",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Oncodesign Société Anonyme",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCODESIGN",
    "state": null,
    "summary": "Oncodesign SociÃ©tÃ© Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.",
    "website": "http://www.oncodesign.com",
    "zipcode": "21076"
  },
  "ALONX.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Onxeo SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONXEO",
    "state": null,
    "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
    "website": "http://www.onxeo.com",
    "zipcode": "75015"
  },
  "ALPAT.PA": {
    "city": "VandÅuvre-lÃ¨s-Nancy",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Plant Advanced Technologies SA",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PLANT ADVANCED",
    "state": null,
    "summary": "Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. The company's technologies include PAT Plant Milking that produces active extracts through plant stimulation and living-root exudation while preserving plants; PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes; and PAT Friday, a recombinant protein expression system using natural protein excretion system of genetically modified carnivorous plants to produce outside their leaf in a sterile closed pitcher. Plant Advanced Technologies SA was founded in 2005 and is headquartered in VandÂuvre-lÃ¨s-Nancy, France.",
    "website": "http://www.plantadvanced.com",
    "zipcode": "54500"
  },
  "ALPHA.PA": {
    "city": "Issy-les-Moulineaux",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Pharnext SA",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARNEXT",
    "state": null,
    "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
    "website": "http://www.pharnext.com",
    "zipcode": "92130"
  },
  "ALPHE.PA": {
    "city": "Romainville",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Pherecydes Pharma Société anonyme",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHERECYDES PHARMA",
    "state": null,
    "summary": "Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.",
    "website": "http://www.pherecydes-pharma.com",
    "zipcode": "93230"
  },
  "ALQGC.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Quantum Genomics Société Anonyme",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "QUANTUM GENOMICS",
    "state": null,
    "summary": "Quantum Genomics SociÃ©tÃ© Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension; and in Phase IIb clinical trial for heart failure. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company was founded in 2005 and is based in Paris, France.",
    "website": "http://www.quantum-genomics.com",
    "zipcode": "75008"
  },
  "ALSEN.PA": {
    "city": "Montpellier",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Sensorion SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SENSORION",
    "state": null,
    "summary": "Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company's pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders. Sensorion SA has a collaboration agreement with Institut Pasteur for gene therapy program to restore auditory functions. The company was founded in 2009 and is headquartered in Montpellier, France.",
    "website": "http://www.sensorion.com",
    "zipcode": "34080"
  },
  "ALTHX.PA": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Theranexus Société Anonyme",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "THERANEXUS",
    "state": null,
    "summary": "Theranexus sociÃ©tÃ© anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.",
    "website": "http://www.theranexus.com",
    "zipcode": "69008"
  },
  "ALVAL.PA": {
    "city": "PÃ©rigny",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Valbiotis SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VALBIOTIS",
    "state": null,
    "summary": "Valbiotis SA engages in the research and development of health nutrition products to prevent metabolic diseases in response to unmet medical needs. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070 for hypercholesterolemia; TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease; and TOTUM-854 for arterial hypertension. It has a strategic partnership with NestlÃ© Health Science. The company was founded in 2014 and is headquartered in PÃ©rigny, France.",
    "website": "http://www.valbiotis.com",
    "zipcode": "17180"
  },
  "AYJ.F": {
    "city": "Saint-Herblain",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Valneva SE",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VALNEVA SE  EO -,15",
    "state": null,
    "summary": "Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",
    "website": "http://valneva.com",
    "zipcode": "44800"
  },
  "BPTS": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Biophytis SA",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Biophytis SA",
    "state": null,
    "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.",
    "website": "http://www.biophytis.com",
    "zipcode": "75005"
  },
  "C4X.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Onxeo SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONXEO S.A. AC.PORT.EO-,25",
    "state": null,
    "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
    "website": "http://www.onxeo.com",
    "zipcode": "75015"
  },
  "CLLS": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Cellectis S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Cellectis S.A.",
    "state": null,
    "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.",
    "website": "http://www.cellectis.com",
    "zipcode": "75013"
  },
  "CMVLF": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Cellectis S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELLECTIS",
    "state": null,
    "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.",
    "website": "http://www.cellectis.com",
    "zipcode": "75013"
  },
  "COX.PA": {
    "city": "Valbonne",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Nicox S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NICOX",
    "state": null,
    "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
    "website": "http://www.nicox.com",
    "zipcode": "06560"
  },
  "DBV.F": {
    "city": "Montrouge",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "DBV Technologies S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DBV TECHNOLOGIES  EO -,10",
    "state": null,
    "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
    "website": "http://www.dbv-technologies.com",
    "zipcode": "92120"
  },
  "DBV.PA": {
    "city": "Montrouge",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "DBV Technologies S.A.",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DBV TECHNOLOGIES",
    "state": null,
    "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
    "website": "http://www.dbv-technologies.com",
    "zipcode": "92120"
  },
  "DBVA.F": {
    "city": "Montrouge",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "DBV Technologies S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DBV TECH.SP.ADR 1/2 EO-10",
    "state": null,
    "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
    "website": "http://www.dbv-technologies.com",
    "zipcode": "92120"
  },
  "DBVT": {
    "city": "Montrouge",
    "country": "France",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "DBV Technologies S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "DBV Technologies S.A.",
    "state": null,
    "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with NestlÃ© Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
    "website": "http://www.dbv-technologies.com",
    "zipcode": "92120"
  },
  "ERYP": {
    "city": "Lyon",
    "country": "France",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "ERYTECH Pharma S.A.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Erytech Pharma S.A.",
    "state": null,
    "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",
    "website": "http://www.erytech.com",
    "zipcode": "69008"
  },
  "ERYP.PA": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "ERYTECH Pharma S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ERYTECH PHARMA",
    "state": null,
    "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",
    "website": "http://www.erytech.com",
    "zipcode": "69008"
  },
  "FALG.PA": {
    "city": "Libourne",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Fermentalg Société Anonyme",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "FERMENTALG",
    "state": null,
    "summary": "Fermentalg SociÃ©tÃ© Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.",
    "website": "http://www.fermentalg.com/fr",
    "zipcode": "33500"
  },
  "G061.F": {
    "city": "LabÃ¨ge",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Genkyotex SA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GENKYOTEX S.A. EO 1,-",
    "state": null,
    "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in LabÃ¨ge, France.",
    "website": "http://www.genkyotex.com",
    "zipcode": "31670"
  },
  "G49N.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "GenSight Biologics S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GENSIGHT BIOLOG. EO -,025",
    "state": null,
    "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.",
    "website": "http://www.gensight-biologics.com",
    "zipcode": "75012"
  },
  "GKTX.PA": {
    "city": "LabÃ¨ge",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Genkyotex SA",
    "market": "fr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GENKYOTEX",
    "state": null,
    "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in LabÃ¨ge, France.",
    "website": "http://www.genkyotex.com",
    "zipcode": "31670"
  },
  "GNFT": {
    "city": "Loos",
    "country": "France",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Genfit S.A.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENFIT S.A.",
    "state": null,
    "summary": "Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",
    "website": "http://www.genfit.com",
    "zipcode": "59120"
  },
  "GNFT.PA": {
    "city": "Loos",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Genfit SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENFIT",
    "state": null,
    "summary": "Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",
    "website": "http://www.genfit.com",
    "zipcode": "59120"
  },
  "GNFTF": {
    "city": "Loos",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Genfit SA",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENFIT",
    "state": null,
    "summary": "Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",
    "website": "http://www.genfit.com",
    "zipcode": "59120"
  },
  "IDD.F": {
    "city": "Marseille",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Innate Pharma S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INNATE PHARMA  EO -,05",
    "state": null,
    "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
    "website": "http://www.innate-pharma.com",
    "zipcode": "13009"
  },
  "IDDA.MU": {
    "city": "Marseille",
    "country": "France",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Biotechnology",
    "long_name": "Innate Pharma S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INNATE PHARMA SP.ADR/1",
    "state": null,
    "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
    "website": "http://www.innate-pharma.com",
    "zipcode": "13009"
  },
  "INRLF": {
    "city": "Saint-Herblain",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Valneva SE",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VALNEVA SE",
    "state": null,
    "summary": "Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",
    "website": "http://valneva.com",
    "zipcode": "44800"
  },
  "IPH.PA": {
    "city": "Marseille",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Innate Pharma S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INNATE PHARMA",
    "state": null,
    "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
    "website": "http://www.innate-pharma.com",
    "zipcode": "13009"
  },
  "IPHA": {
    "city": "Marseille",
    "country": "France",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Innate Pharma S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Innate Pharma S.A.",
    "state": null,
    "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
    "website": "http://www.innate-pharma.com",
    "zipcode": "13009"
  },
  "IPHYF": {
    "city": "Marseille",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Innate Pharma S.A.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INNATE PHARMA",
    "state": null,
    "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
    "website": "http://www.innate-pharma.com",
    "zipcode": "13009"
  },
  "IVA": {
    "city": "Daix",
    "country": "France",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Inventiva S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Inventiva S.A. - American Depos",
    "state": null,
    "summary": "Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
    "website": "http://www.inventivapharma.com",
    "zipcode": "21121"
  },
  "IVA.PA": {
    "city": "Daix",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Inventiva S.A.",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INVENTIVA",
    "state": null,
    "summary": "Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
    "website": "http://www.inventivapharma.com",
    "zipcode": "21121"
  },
  "JEH.F": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "genOway Société anonyme",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GENOWAY S.A. INH.  EO-,60",
    "state": null,
    "summary": "genOway SociÃ©tÃ© anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.",
    "website": "http://www.genoway.com",
    "zipcode": "69007"
  },
  "LYS.PA": {
    "city": "Neuilly-sur-Seine",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Lysogene S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LYSOGENE",
    "state": null,
    "summary": "Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.",
    "website": "http://www.lysogene.com",
    "zipcode": "92200"
  },
  "MDCLF": {
    "city": "Jacou",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "MedinCell S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MEDINCELL SA",
    "state": null,
    "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
    "website": "http://www.medincell.com",
    "zipcode": "34830"
  },
  "MEB.F": {
    "city": "Jacou",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "MedinCell S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDINCELL S.A.  EO-,01",
    "state": null,
    "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
    "website": "http://www.medincell.com",
    "zipcode": "34830"
  },
  "MEDCL.PA": {
    "city": "Jacou",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "MedinCell S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDINCELL",
    "state": null,
    "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
    "website": "http://www.medincell.com",
    "zipcode": "34830"
  },
  "NANO.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Nanobiotix S.A.",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOBIOTIX",
    "state": null,
    "summary": "Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.",
    "website": "http://www.nanobiotix.com",
    "zipcode": "75012"
  },
  "NBTX": {
    "city": "Paris",
    "country": "France",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Nanobiotix S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Nanobiotix S.A.",
    "state": null,
    "summary": "Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.",
    "website": "http://www.nanobiotix.com",
    "zipcode": "75012"
  },
  "NICXF": {
    "city": "Valbonne",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Nicox S.A.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NICOX SA",
    "state": null,
    "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
    "website": "http://www.nicox.com",
    "zipcode": "06560"
  },
  "NXOA.F": {
    "city": "Valbonne",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Nicox S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NICOX SA INH.  EO 1",
    "state": null,
    "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
    "website": "http://www.nicox.com",
    "zipcode": "06560"
  },
  "ONXEO.CO": {
    "city": "Paris",
    "country": "France",
    "currency": "DKK",
    "exchange": "CPH",
    "industry": "Biotechnology",
    "long_name": "Onxeo SA",
    "market": "dk_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Onxeo SA",
    "state": null,
    "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
    "website": "http://www.onxeo.com",
    "zipcode": "75015"
  },
  "OSE.PA": {
    "city": "Nantes",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "OSE Immunotherapeutics SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OSE IMMUNO",
    "state": null,
    "summary": "OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as SjÃ¶gren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.",
    "website": "http://www.ose-immuno.com",
    "zipcode": "44200"
  },
  "P0X.F": {
    "city": "Issy-les-Moulineaux",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharnext SA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARNEXT  EO-,01",
    "state": null,
    "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
    "website": "http://www.pharnext.com",
    "zipcode": "92130"
  },
  "P0X.SG": {
    "city": "Issy-les-Moulineaux",
    "country": "France",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Pharnext SA",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Pharnext Actions Nom. EO-,01",
    "state": null,
    "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
    "website": "http://www.pharnext.com",
    "zipcode": "92130"
  },
  "PNEXF": {
    "city": "Issy-les-Moulineaux",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Pharnext SA",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PHARNEXT",
    "state": null,
    "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
    "website": "http://www.pharnext.com",
    "zipcode": "92130"
  },
  "POXEL.PA": {
    "city": "Lyon",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Poxel S.A.",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "POXEL",
    "state": null,
    "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.",
    "website": "http://www.poxelpharma.com",
    "zipcode": "69007"
  },
  "RFM.F": {
    "city": "Montpellier",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Sensorion SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SENSORION  EO -,10",
    "state": null,
    "summary": "Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company's pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders. Sensorion SA has a collaboration agreement with Institut Pasteur for gene therapy program to restore auditory functions. The company was founded in 2009 and is headquartered in Montpellier, France.",
    "website": "http://www.sensorion.com",
    "zipcode": "34080"
  },
  "RFM.SG": {
    "city": "Montpellier",
    "country": "France",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Sensorion SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Sensorion S.A. Actions au Porte",
    "state": null,
    "summary": "Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company's pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders. Sensorion SA has a collaboration agreement with Institut Pasteur for gene therapy program to restore auditory functions. The company was founded in 2009 and is headquartered in Montpellier, France.",
    "website": "http://www.sensorion.com",
    "zipcode": "34080"
  },
  "SIGHT.PA": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "GenSight Biologics S.A.",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GENSIGHT BIOLOGICS",
    "state": null,
    "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.",
    "website": "http://www.gensight-biologics.com",
    "zipcode": "75012"
  },
  "TGNA.F": {
    "city": "Illkirch-Graffenstaden",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Transgene SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TRANSGENE SA  EO 0,50",
    "state": null,
    "summary": "Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
    "website": "http://www.transgene.fr",
    "zipcode": "67405"
  },
  "TNG.PA": {
    "city": "Illkirch-Graffenstaden",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Transgene SA",
    "market": "fr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TRANSGENE",
    "state": null,
    "summary": "Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
    "website": "http://www.transgene.fr",
    "zipcode": "67405"
  },
  "TRGNF": {
    "city": "Illkirch-Graffenstaden",
    "country": "France",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Transgene SA",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "TRANSGENE",
    "state": null,
    "summary": "Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma (stomach, pancreas, and colon); and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. It also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. Transgene SA has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
    "website": "http://www.transgene.fr",
    "zipcode": "67405"
  },
  "VLA.PA": {
    "city": "Saint-Herblain",
    "country": "France",
    "currency": "EUR",
    "exchange": "PAR",
    "industry": "Biotechnology",
    "long_name": "Valneva SE",
    "market": "fr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VALNEVA",
    "state": null,
    "summary": "Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",
    "website": "http://valneva.com",
    "zipcode": "44800"
  },
  "XUP.F": {
    "city": "Loos",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Genfit SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENFIT S.A.  EO -,25",
    "state": null,
    "summary": "Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",
    "website": "http://www.genfit.com",
    "zipcode": "59120"
  },
  "XUP.SG": {
    "city": "Loos",
    "country": "France",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Genfit SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Genfit S.A. Actions au Port. EO",
    "state": null,
    "summary": "Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",
    "website": "http://www.genfit.com",
    "zipcode": "59120"
  },
  "XUPB.MU": {
    "city": "Loos",
    "country": "France",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Biotechnology",
    "long_name": "Genfit SA",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENFIT S.A.  ADR/1 EO-,25",
    "state": null,
    "summary": "Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.",
    "website": "http://www.genfit.com",
    "zipcode": "59120"
  },
  "ZVA.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cellectis S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELLECTIS NOM.  EO-,05",
    "state": null,
    "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.",
    "website": "http://www.cellectis.com",
    "zipcode": "75013"
  },
  "ZVAA.F": {
    "city": "Paris",
    "country": "France",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cellectis S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELLECTIS SP.ADR 1 EO-,05",
    "state": null,
    "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.",
    "website": "http://www.cellectis.com",
    "zipcode": "75013"
  }
}
